{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"description":"Response is evaluated based on Recommended Response Criteria for Waldenstrom's Macroglobulinemia (WM). Minor response is defined as achieving minor response (MR) or better (including complete response \\[CR\\], near CR (nCR), very good partial remission \\[VGPR\\], partial response \\[PR\\] and MR).\n\nCR: Disappearance of monoclonal protein by immmunofixation; no histologic evidence of bone marrow involvement, resolution of any adenopathy/organomegaly, or signs or symptoms attributable to WM nCR: As CR except that immunofixation is still positive VGPR: At least 90% reduction of serum monoclonal protein using serum protein electrophoresis PR: At least 50% reduction of serum monoclonal concentration on protein electrophoresis and at least a decrease in adenopathy/organomegaly (confirmed by original mode of imaging). No new signs or symptoms of active disease.\n\nMR: At least 25% but less than 50% reduction of serum monoclonal protein and no new signs or symptoms of active disease.","groups":[{"description":"Patients receive rituximab IV over 30-60 minutes on days 1, 8, 15, and 22 (of courses 1 and 4 only) and bortezomib IV or SC and dexamethasone PO on days 1, 8, and 15. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Arm E (Phase II: Rituximab, Bortezomib, Dexamethasone)"},{"description":"Patients receive temsirolimus IV over 30-60 minutes on days 1, 8, 15, and 22 and rituximab, bortezomib, and dexamethasone as in arm E. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.","id":"OG001","title":"Arm F (Phase II: Temsirolimus, Rituximab, Bortezomib, Dexamethasone)"}],"populationDescription":"No patients were enrolled in the phase II part of this study.","reportingStatus":"POSTED","timeFrame":"Assessed at cycle 6","title":"Phase II: Minor Response Rate","type":"SECONDARY"}